Pharmaceutical manufacturing efficiency, drug prices, and public health: Examining the causal links

Drug Information Journal

Volumn 41, Issue 2, 2007, Pages 229-239

  Vernon, John A ^a   Hughen, W Keener ^b   Trujillo, Antonio J ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Drug prices; Pharmaceutical manufacturing; R D

Indexed keywords

DRUG;

CONFERENCE PAPER; DRUG COST; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; MODEL; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH; UNITED STATES;

EID: 33947201624     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100217     Document Type: Conference Paper

References (26)

1. US Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medicinal products. 2004. Available at: http://www.fda.gov/cdrh/ocd/ criticalpath.html. Accessed May 5, 2006.
2. Bruttin F, Dean D. The Metamorphosis of Manufacturing-From Art to Science. Somers, NY: 2005. IBM Institute for Business Value, IBM Corp., Publication G510-4034-01.
3. Dean D, Bruttin F. Risk and the economics of regulatory compliance. PDA J Pharm Technol., 2000; 54:253-263.
4. Pisano G. The Development Factory-Unlocking the Potential of Process Innovation: Lessons From Pharmaceuticals and Biotechnology. Cambridge, MA: Harvard Business School Press; 1997.
5. Dean D, Bruttin F. Discovery is not enough-how a new compliance agenda is changing the face of the industry. Drug Discovery World. 2005:9-14.
6. Cooney C. Benchmarking pharmaceutical manufacturing performance. Working paper in: MIT Program on the Pharmaceutical Industry (POPI); Cambridge, MA; 1996:33-96.
7. Nelson R, Winter S. An Evolutionary Theory of Economic Change. Cambridge, MA: Harvard University Press; 1982.
8. Caves R, Whinston M, Hurwitz M. Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics; 1991:1-66.
9. Comanor W. The political economy of the pharmaceutical industry. J Econ Lit. 1986; 24.
10. Tirole J. The Theory of Industrial Organization. Cambridge, MA: MIT Press; 1988.
11. Coulson E, Stuart B. Insurance choice and the demand for prescription drugs. South Econ J. 1995;61:1146-1157.
12. Santerre R, Vernon J. Simulating Consumer Gains From a Ceiling on Drug Prices. Cambridge, MA: National Bureau of Economic Research; 2005. Working Paper 11139.
13. Abbott T, Vernon J. A Financial Simulation Model of the Firm Pharmaceutical R&D Investment Decision: Implications for a New US Price Control Policy. Cambridge, MA: National Bureau of Economic Research; 2005. Working Paper 11114.
14. Patented Medicine Prices Review Board. 2004 annual report. Available at: http://www.pmprb-cepmb.gc.ca/english/view.asp?x=436& mid=383. Accessed August 9, 2005.
15. Office of Management and Budget. Circular A-94, Transmittal Memo No. 64. Available at: http://www.whitehouse.gov/omb/circulars/a094 /a094.html. Accessed August 9, 2005.
16. Reinhardt U. Perspectives on the pharmaceutical industry. Health Aff. 2001;20(5):136-149.
17. Vernon J. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 2005;14:1-17.
18. Pharmaceutical Research and Manufacturers of America. Pharmaceutical industry profile. Available at: http://www.phrma.org/publications/ publications//2005-03-17.1143.pdf. Accessed August 9, 2005.
19. Scherer F. The link between gross profitability and pharmaceutical R&D spending. Health Aff. 2001;20:216-220.
20. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151- 185.
21. Brealey R, Myers S. Principles of Corporate Finance. New York, NY: McGraw-Hill/Irwin; 2003.
22. Vernon J. New evidence on drug price controls. Regulation. 2004;27:13-14.
23. Golec J, Vernon J. Pharmaceutical reimportation: the European experience-what the United States can expect. Managed Care. 2004;13.
24. Lichtenberg. Sources of U.S. Longevity Increase, 1960-1997. Cambridge, MA: National Bureau of Economic Research; 2002. Working Paper 8755.
25. Murphy K, Topel R. Measuring the Gains from Medical Research. University of Chicago Press; 2003.
26. World Fact Book. Central Intelligence Agency (CIA). Available at: http://www.cia.gov/cia/ publications/factbook/rankorder/2001rank.html. Accessed August 9, 2005.